Institutul Regional de Oncologie Iasi
Iasi, Romania
University hospital in Iași
Strada General Henri Mathias Berthelot 2-4, Iași 700483
About Institutul Regional de Oncologie Iasi
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Amgen
6
Hoffmann-La Roche
5
Daiichi Sankyo, Inc.
2
EMD Serono Research & Development Institute, Inc.
2
Institut de Recherches Internationales Servier
2
NanoCarrier Co., Ltd.
2
Synta Pharmaceuticals Corp.
2
Astex Pharmaceuticals, Inc.
1
Bayer
1
Boehringer Ingelheim
1
Bristol-Myers Squibb
1
Clinical Trials at Institutul Regional de Oncologie Iasi
During the past decade, Institutul Regional de Oncologie Iasi conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 12 clinical trials were completed, i.e. on
average, 48% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 7 clinical trials were completed. i.e. 116.7%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
2006-09-20
2017-12-11
Completed
1,276
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
2006-09-01
2014-06-01
Completed
1,252
EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients
2007-01-01
2011-03-01
Completed
143
Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma
2007-08-01
2009-06-01
Terminated
630
A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.
2007-11-01
2010-01-01
Completed
360
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
2009-02-04
2018-06-03
Completed
233
LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer
2008-12-03
2017-11-13
Completed
1,314
Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer
2008-12-01
2012-08-01
Completed
111
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Institutul Regional de Oncologie Iasi" #1 sponsor was "Amgen" with 6 trials, followed by "Hoffmann-La Roche" with 5 trials
sponsored, "Daiichi Sankyo, Inc." with 2 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 2 trials sponsored and "Institut de Recherches Internationales Servier"
with 2 trials sponsored. Other sponsors include 19 different institutions and
companies that sponsored additional 27 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Institutul Regional de Oncologie Iasi"
#1 collaborator was "ADIR, a Servier Group company" with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "BeiGene, Ltd." with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were
collaborators in the rest 11 trials.
Clinical Trials Conditions at Institutul Regional de Oncologie Iasi
According to Clinical.Site data, the most researched conditions in "Institutul Regional de Oncologie Iasi" are
"Metastatic Colorectal Cancer" (3 trials), "Breast Cancer" (2 trials), "Chemotherapy-induced Thrombocytopenia" (2 trials), "Non-small Cell Lung Cancer" (2 trials) and "Advanced Breast Cancer" (1 trials). Many other conditions were trialed in "Institutul Regional de Oncologie Iasi" in a lesser frequency.
Clinical Trials Intervention Types at Institutul Regional de Oncologie Iasi
Most popular intervention types in "Institutul Regional de Oncologie Iasi" are "Drug" (37 trials), "Biological" (4 trials), "Other" (4 trials), "Diagnostic Test" (2 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.
The name of intervention was led by "Paclitaxel" (7 trials), "Placebo" (7 trials), "Capecitabine" (5 trials), "Carboplatin" (5 trials) and "Cisplatin" (4 trials). Other intervention names were less common.
Clinical Trials Genders at Institutul Regional de Oncologie Iasi
The vast majority of trials in "Institutul Regional de Oncologie Iasi" are
36 trials for "All" genders and 5 trials for "Female" genders.
Clinical Trials Status at Institutul Regional de Oncologie Iasi
Currently, there are NaN active trials in "Institutul Regional de Oncologie Iasi".
undefined are not yet recruiting,
8 are recruiting,
5 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 22 completed trials in Institutul Regional de Oncologie Iasi,
undefined suspended trials,
and 4 terminated clinical trials to date.
Out of the total trials that were conducted in Institutul Regional de Oncologie Iasi, 3 "Phase 1"
clinical trials were conducted, 13 "Phase 2" clinical
trials and 24 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 1 trials that are defined as “Not Applicable".
Departments of Institutul Regional de Oncologie Iasi
Institutul Regional de Oncologie Iasi has several departments that took part in Clinical trials: "Institutul Regional de Oncologie Iasi; Clinica de Hematologie" - 6 trials
Departments List
Name
City
Trials